Efficacy, Safety and Tolerability of ATH3G10 in Patients With ST-elevation Myocardial Infarction

• Status: Completed
• Trial end date: 2021-04-19
• Target enrollment: 0
• Participant gender: All

Summary

Patients with ST-segment elevation myocardial infarction (STEMI) that have suffered a major anterior wall infarction or where coronary blood flow is less than normal in spite of successful percutaneous coronary intervention (PCI) have a poor prognosis. There are today no medical treatments that specifically reduce risk in these patients. The acute inflammatory reaction in conjunction with a STEMI and reperfusion by PCI determines the final size of the infarction and the signals leading to left ventricular remodelling.

This study is designed to assess the efficacy and safety of single intravenous injection with ATH3G10, a fully human IgG1 antibody against phosphorylcholine, in high-risk subjects with STEMI. ATH3G10 aims to reduce inflammation and thereby infarction size and remodeling.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Athera Biotechnologies AB
• Treatments: Antibodies, Monoclonal

Criteria

Inclusion Criteria:

• Acute myocardial infarction with ST elevation at the J-point in two contiguous leads

• Start of PCI less than 4 hours after symptom onset.

Exclusion Criteria:

• Cardiogenic chock, non-compensated acute heart failure and/or pulmonary edema.

• Previous major vascular intervention within the last 4 weeks.

• History of an infarct in the same artery that is currently affected.

• Conditions contraindicating MRI